| Entries |
| Document | Title | Date |
|---|
| 20080226719 | Combination of Rosiglitazone and Donepezil for Improvement of Cognitive Function - Disclosed is a pharmaceutical composition comprising both rosiglitazone or a pharmaceutically acceptable salt thereof and donepezil or a pharmaceutically acceptable salt thereof which is of use in the treatment or prophylaxis of Alzheimer's disease or other dementias and mild cognitive impairment. Also disclosed is an oral dosage forms comprising rosiglitazone or a pharmaceutically acceptable salt thereof and donepezil or a pharmaceutically acceptable salt thereof. | 09-18-2008 |
| 20090202636 | Pharmaceutical Composition - A stable formulation of telmisartan and hydrochlorothiazide having both substances in separate units is prepared, exhibiting exceptional stability when subjecting to stress conditions. | 08-13-2009 |
| 20090208575 | Pharmaceutical Composition Of Acid Labile Substances - A pharmaceutical composition for oral use comprising a) a core comprising an effective amount of benzimidazole and an organic stabilizing agent which is present in an amount effective to stabilize the composition, b) an intermediate layer comprising of a water insoluble polymer and an organic stabilizer, and c) an outer enteric coating layer. The organic stabilizing agent is present in the core from about 1% to about 10% by weight of the core and in the intermediate layer from about 5% to about 35% by weight of intermediate layer. | 08-20-2009 |
| 20090214647 | Compositions For Enternal Application Of Microorganisms - The present invention describes a process for the manufacture of a solid composition comprising a microorganism, which process comprises a first step of blending and/or compacting the microorganism with a salt of a medium or long-chain fatty acid to prepare a powderous mixture or compacted granulate, and a second step of providing said powderous mixture or compacted granulate with a coating. The microorganisms are preferably probiotics. The invention also relates to the solid composition obtained by said process and to its use in food. | 08-27-2009 |
| 20090220598 | Stable Oral Pharmaceutical Composition Containing Thyroid Hormone Receptor Agonists - Compositions are described in which certain thyroid hormone receptor-binding compounds are formulated together with either an enteric coating, an antioxidant, or both an enteric coating and an antioxidant. Such formulation acts to prevent the formation of undesired reaction products in vivo. | 09-03-2009 |
| 20090220599 | Antifungal formulation and manufacturing method thereof - A new antifungal formulation is provided. The present invention uses a sterol modified with polyethylene glycol (PEG) as a drug carrier. The drug carrier encapsulates Amphotericin B (AmB) by self-assembly to form polymeric micelles. The polymeric micelles can reduce toxicity of Amphotericin B and control release of Amphotericin B. The polymeric micelles of Amphotericin B are used as a new antifungal formulation. | 09-03-2009 |
| 20100062064 | Method for Delivering A Pharmaceutical Composition to Patient in Need Thereof - The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof | 03-11-2010 |
| 20100074950 | ANTI-DIABETIC COMBINATIONS - A pharmaceutical composition comprising a dipeptidyl peptidase IV inhibitor and a slow release biguanide is provided. A method for treating diabetes in a patient in need thereof including administering an anti-diabetic combination comprising a DPP inhibitor and a slow release biguanide is also provided. | 03-25-2010 |
| 20100172987 | Three Layer Tablet Containing Cetirizine, Pseudoephedrine, and Naproxen - In one aspect, the present invention features a tablet including a first drug layer, a second drug layer, and a third drug layer, wherein (i) the first drug layer includes naproxen; (ii) a second drug layer including pseudoephedrine; and (iii) the third drug layer includes cetirizine; wherein the first drug layer is in contact with the second drug layer, the third drug layer is in contact with the second drug layer, and the first drug layer is not in contact with the third drug layer, and wherein the second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours. | 07-08-2010 |
| 20100189790 | Delayed release rasagiline formulation - Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. | 07-29-2010 |
| 20100233261 | Pharmaceutical Composition Comprising Amlodipine and Losartan - Disclosed herein is a pharmaceutical composition comprising a part containing amlodipine or a pharmaceutically acceptable salt thereof and another separate part containing losartan or a pharmaceutically acceptable salt thereof, which exhibits improved preventive and therapeutic effects against cardiovascular disorders. | 09-16-2010 |
| 20100247649 | PHARMACEUTICAL FORMULATIONS COMPRISING TELMISARTAN AND HYDROCHLOROTHIAZIDE - Pharmaceutical tablets comprising a first layer formulated for immediate release of telmisartan from a dissolving matrix and a second layer formulated for immediate release of hydrochlorothiazide from a dissolving matrix, methods for producing tablets and methods of use for treating hypertension. | 09-30-2010 |
| 20110229571 | Pharmaceutical Compositions Comprising a Selective I1 Imidazoline Receptor Agonist and an Angiotensin II Receptor Blocker - Pharmaceutical compositions containing selective imidazoline receptor agonists combined with angiotensin II receptor blockers, particularly, pharmaceutical compositions containing Moxonidine and Eprosartan mesylate, as well as the use of such compositions for the treatment of hypertension, especially in hypertensive patients suffering from type II diabetes or susceptible to developing type II diabetes. | 09-22-2011 |
| 20110236482 | Composition For The Prevention And Treatment Of Viral Infections - The invention relates to a composition comprising an extract of the genus | 09-29-2011 |
| 20110250273 | COMPOSITIONS OF PROTON PUMP INHIBITORS, KITS AND METHODS OF THEIR USE TO TREAT DIABETES - The present invention relates to compositions, kits and methods of treating diabetes. More specifically, compositions of at least one proton pump inhibitor, kits and methods of their use to treat diabetes. | 10-13-2011 |
| 20110280940 | Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy - The invention relates to the medical field, more precisely in the field of anti-cancer treatment and treatment of Alzheimer's disease, Parkinson's disease or Pick's disease or for ameliorating symptoms of Down syndrome, providing newly synthesised multi-vanilloyl derivative compounds and their use in the treatment of said disorders. | 11-17-2011 |
| 20110280941 | COMPOSITIONS OF PROTON PUMP INHIBITORS AND INSULIN SECRETAGOGUES, AND METHODS OF THEIR USE TO TREAT DIABETES - The present invention relates to compositions, kits and methods of treating diabetes. More specifically, compositions of at least one proton pump inhibitor and at least one insulin secretagogue, kits and methods of their use to treat diabetes. | 11-17-2011 |
| 20110305758 | ORALLY DISINTEGRATING TABLET HAVING INNER CORE - The present invention provides an orally disintegrating tablet with improved photostability of a medicament unstable to light. The orally disintegrating tablet has an inner core and an outer layer that covers the surface of the inner core, wherein the inner core contains the medicament unstable to light and the outer layer contains a light-absorbing substance such as Red No. 2, Red No. 3, Yellow No. 4, Yellow No. 5, Blue No. 1, Red No. 3 aluminum lake, Yellow No. 4 aluminum lake, Yellow No. 5 aluminum lake, Blue No. 1 aluminum lake, Blue No. 2 aluminum lake, red ferric oxide, yellow ferric oxide, black iron oxide, carmine, or sodium copper chlorophyllin. | 12-15-2011 |
| 20120100214 | Sustained-Release Tablet and Process for Preparing the Same - A method for producing a sustained-release tablet having improved stability and content uniformity is provided. The method involves first preparing a core tablet by granulating, drying, milling, blending, and compressing a mixture of active and inactive ingredients. Four coating layers are applied to the core tablet: an inner layer, an enteric coating layer, an active layer, and an outer layer. The active ingredient may be a tetracycline, such as doxycycline. A sustained-release tablet prepared according to the method is also described. | 04-26-2012 |
| 20130034606 | IMMEDIATE RELEASE TABLET FORMULATIONS - The present invention provides an immediate release pharmaceutical formulation which includes a tablet or capsule formulation comprising metformin and the sodium dependent glucose transporter (SGLT2) inhibitor dapagliflozin or its propylene glycol hydrate. The present invention also provides methods of preparing the formulations and methods of treating diseases or disorders associated with SGLT2 activity employing these formulations. | 02-07-2013 |
| 20130309302 | Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil - The present invention relates to manufacturing processes for the preparation of a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil and optionally at least one diuretic characterized in that nifedipine is released in the body in a controlled (modified) manner and the candesartan cilexetil is released rapidly (immediate release (IR)) and optionally the diuretic is released rapidly (immediate release (IR)) and the pharmaceutical dosage forms obtainable by these processes. | 11-21-2013 |
| 20140023710 | MILNACIPRAN FORMULATIONS - The present invention provides formulations comprising milnacipran or pharmaceutically acceptable salts thereof (e.g., milnacipran hydrochloride), including immediate release formulations and modified formulations, such as delayed release and extended release formulations. The present invention provides formulations with improved stability and high bioavailability. Processes for preparing the formulations as well as methods of treating conditions by administering the formulations are also described. | 01-23-2014 |
| 20140248350 | DELAYED RELEASE FILM COATINGS CONTAINING CALCIUM SILICATE AND SUBSTRATES COATED THEREWITH - The present invention includes pH dependent, dry film coating compositions containing calcium silicate for use on orally-ingestible substrates such as tablets and the like. The film coating compositions can be applied as an aqueous suspension either directly to a substrate or after the substrate has been coated with a subcoat. In preferred aspects, the polymer is either an enteric or reverse-enteric polymer. Methods of preparing the dry film coatings, methods of preparing corresponding aqueous suspensions, methods of applying the coatings to substrates and the coated substrates themselves are also disclosed. | 09-04-2014 |
| 20140271857 | BENZONATATE MODIFIED RELEASE SOLID TABLETS AND CAPSULES - A 12-hour anti-tussive modified release solid tablet or capsule is described which comprises a benzonatate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay. The modified release may be provided by (a) a high melt temperature, water-insoluble wax or waxy substance, (b) a low viscosity hydrophilic polymer such a hydroxypropyl methylcellulose, (c) a reverse enteric coating, or combinations thereof. The benzonatate may be in an adsorbate with a silico or silicate or in a complex with a weak acidic ion exchange resin complex. | 09-18-2014 |
| 20140294958 | LUBRICIOUS COATINGS - The present invention relates to lubricious coatings comprising an ionomer and a hydrophilic polymer wherein the ionomer is cross-linked using a suitable cross-linking agent, and optionally also conventional excipients, such as a surfactant, a plasticizer and/or a filler. The invention also relates to pharmaceutical products covered by such lubricious coatings, compositions for preparing these lubricious coatings and a method for providing pharmaceutical products with these lubricious coatings. | 10-02-2014 |
| 20150118305 | COMPOSITIONS COMPRISING SULFORAPHANE OR A SULFORAPHANE PRECURSOR AND URSOLIC ACID - The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and ursolic acid, a salt, ester, amide, or derivative thereof. The invention also relates to the combination of a sulforaphane or a derivative thereof and ursolic acid, a salt, ester, amide, or derivative thereof. The invention also relates to the combination of a broccoli extract or powder and ursolic acid, a salt, ester, amide, or derivative thereof. The invention provides compositions and methods relating to these combinations. | 04-30-2015 |
| 20150118306 | COMPOSITIONS COMPRISING SULFORAPHANE OR A SULFORAPHANE PRECURSOR AND A MILK THISTLE EXTRACT OR POWDER - The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a milk thistle extract or powder. The invention also relates to the combination of a sulforaphane or a derivative thereof and a milk thistle extract or powder. The invention also relates to the combination of a broccoli extract or powder and a milk thistle extract or powder. The invention provides compositions and methods relating to these combinations. | 04-30-2015 |
| 20150342921 | METFORMIN-ORLISTAT COMPOSITIONS - This invention provides a combination of a hypoglycemic, metformin, and an irreversible intestinal gastric and pancreatic lipase inhibitor, Orlistat, for a better control of obesity than with the monotherapy used with each of them; this composition provides “low” doses of both drugs to minimize secondary effects and to make use of the synergic effect of both compounds. | 12-03-2015 |
| 20160060305 | USE OF SALMONELLA FLAGELLIN DERIVATIVE IN PREPARATION OF DRUG FOR PREVENTING AND TREATING INFLAMMATORY BOWEL DISEASES - The application of | 03-03-2016 |
| 20180021272 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | 01-25-2018 |
